Lupin Ltd. NSE: LUPIN | BSE: 500257

Mid-range Performer

In 1 Starfolio Basket

Download real time

2089.40 -24.50 (-1.16%)

447.4K

NSE+BSE Volume

NSE 15 Dec, 2025 2:47 PM (IST)

Lupin News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Lupin from all sources in a single place.

Load latest

16 Jul 2025

2089.40

-1.16%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the Unites States

15 Jul 2025

2089.40

-1.16%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copy of Newspaper Advertisement relating to Annual General Meeting, Record Date and other related information.

14 Jul 2025, 05:01PM

2089.40

-1.16%

Corp. Action

Lupin Ltd - 500257 - Intimation Of Record Date For Payment Of Final Dividend, If Declared.

BSE India

Intimation of Record Date for payment of final Dividend, if declared.

14 Jul 2025, 04:53PM

2089.40

-1.16%

AGM

Lupin Ltd - 500257 - Intimation Of The Forty-Third Annual General Meeting Of The Company And …

BSE India

Intimation of the Forty-Third Annual General Meeting of the Company and Record Date for payment of Dividend.

10 Jul 2025

2089.40

-1.16%

Company Update

Lupin Ltd - 500257 - ESG Rating By NSE Sustainability Ratings & Analytics Limited.

BSE India

ESG Rating by NSE Sustainability Ratings & Analytics Limited.

10 Jul 2025

2089.40

-1.16%

Company Update

Lupin Ltd - 500257 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Reg. 74(5) of SEBI (Depositories and Participant) Regulations, 2018, for the quarter ended on June 30, 2025.

10 Jul 2025

2089.40

-1.16%

Lupin, Zentiva Group ink agreement to commercialise biosimilar Certolizumab Pegol

Business Line

Both parties will invest in the development of the new biosimilar

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

09 Jul 2025

2089.40

-1.16%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab.

09 Jul 2025

2089.40

-1.16%

Lupin share pops 2% on licencing and supply agreement with Zentiva; details

Business Standard

Lupin's share price rose in trade today after the company announced a licensing and supply agreement with Zentiva, k.s., for the commercialisation of its biosimilar Certolizumab Pegol.

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

08 Jul 2025

2089.40

-1.16%

Company Update

Lupin Ltd - 500257 - License And Supply Agreement

BSE India

The Company has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of Lupin''s biosimilar Certolizumab Pegol.

Is Lupin Ltd. worth buying?

932 Votes:

Buy 72.75%

Sell 17.6%

Hold 9.66%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >